A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma

Abstract Preoperative prediction of tumor recurrence after radiofrequency ablation (RFA) in patients with early hepatocellular carcinoma (HCC) is helpful for clinical decision-making before treatment. A total of 162 patients with HCC of 3 cm or less who were completely ablated by percutaneous RFA we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Zhu He, Kun He, Rui Qin Huang, Li Wen Liu, Shao Wei Ye, Jun Lin Qian, Peng Peng, Qi Jie Luo, Ze Liang Wang, Ze Min Hu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/755435f48dc141a399063455e8148dbe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:755435f48dc141a399063455e8148dbe
record_format	dspace
spelling	oai:doaj.org-article:755435f48dc141a399063455e8148dbe2021-12-02T14:26:25ZA clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma10.1038/s41598-021-87782-y2045-2322https://doaj.org/article/755435f48dc141a399063455e8148dbe2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87782-yhttps://doaj.org/toc/2045-2322Abstract Preoperative prediction of tumor recurrence after radiofrequency ablation (RFA) in patients with early hepatocellular carcinoma (HCC) is helpful for clinical decision-making before treatment. A total of 162 patients with HCC of 3 cm or less who were completely ablated by percutaneous RFA were divided into a derivation cohort (n = 108) and a validation cohort (n = 54). Based on X-Tiles software, Kaplan–Meier curve analysis and COX multivariate analysis to obtain valuable predictive indicators, a clinical scoring system for predicting tumor recurrence was established. In the verall cohort, derivation cohort and validation cohort, we found circulating tumor cells (CTC) > 2/3.2 mL, alpha-fetoprotein (AFP) > 20 ng/mL, and des-γ-carboxyprothrombin (DCP) > 40 mAU/mL, maximum tumor diameter > 20 mm, and the number of multiple tumors (≥ 2) are independent risk factors affecting tumor recurrence. Each independent risk factor was assigned a score of 1 to construct a predictive clinical scoring system, and X-Tiles software was used to divide the clinical score into a low-risk group (0 score–1 score), a medium-risk group (2 scores–3 scores), and a high-risk group (4 scores–5 scores). The cumulative tumor recurrence rates of patients in the low-risk group, middle-risk group, and high-risk group in 1 year, 2 years, and 3 years were 19.4%/27.5%/30.9%, 37.0%/63.2%/79.9% and 68.2%/100%/100%, respectively (Low-risk group vs medium-risk group: P < 0.001; medium-risk group vs high-risk group: P < 0.001). This clinical scoring system can predict the prognosis of patients with HCC of 3 cm or smaller undergoing percutaneous RFA, which has certain application value for making preoperative clinical decisions.Yong Zhu HeKun HeRui Qin HuangLi Wen LiuShao Wei YeJun Lin QianPeng PengQi Jie LuoZe Liang WangZe Min HuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yong Zhu He Kun He Rui Qin Huang Li Wen Liu Shao Wei Ye Jun Lin Qian Peng Peng Qi Jie Luo Ze Liang Wang Ze Min Hu A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
description	Abstract Preoperative prediction of tumor recurrence after radiofrequency ablation (RFA) in patients with early hepatocellular carcinoma (HCC) is helpful for clinical decision-making before treatment. A total of 162 patients with HCC of 3 cm or less who were completely ablated by percutaneous RFA were divided into a derivation cohort (n = 108) and a validation cohort (n = 54). Based on X-Tiles software, Kaplan–Meier curve analysis and COX multivariate analysis to obtain valuable predictive indicators, a clinical scoring system for predicting tumor recurrence was established. In the verall cohort, derivation cohort and validation cohort, we found circulating tumor cells (CTC) > 2/3.2 mL, alpha-fetoprotein (AFP) > 20 ng/mL, and des-γ-carboxyprothrombin (DCP) > 40 mAU/mL, maximum tumor diameter > 20 mm, and the number of multiple tumors (≥ 2) are independent risk factors affecting tumor recurrence. Each independent risk factor was assigned a score of 1 to construct a predictive clinical scoring system, and X-Tiles software was used to divide the clinical score into a low-risk group (0 score–1 score), a medium-risk group (2 scores–3 scores), and a high-risk group (4 scores–5 scores). The cumulative tumor recurrence rates of patients in the low-risk group, middle-risk group, and high-risk group in 1 year, 2 years, and 3 years were 19.4%/27.5%/30.9%, 37.0%/63.2%/79.9% and 68.2%/100%/100%, respectively (Low-risk group vs medium-risk group: P < 0.001; medium-risk group vs high-risk group: P < 0.001). This clinical scoring system can predict the prognosis of patients with HCC of 3 cm or smaller undergoing percutaneous RFA, which has certain application value for making preoperative clinical decisions.
format	article
author	Yong Zhu He Kun He Rui Qin Huang Li Wen Liu Shao Wei Ye Jun Lin Qian Peng Peng Qi Jie Luo Ze Liang Wang Ze Min Hu
author_facet	Yong Zhu He Kun He Rui Qin Huang Li Wen Liu Shao Wei Ye Jun Lin Qian Peng Peng Qi Jie Luo Ze Liang Wang Ze Min Hu
author_sort	Yong Zhu He
title	A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
title_short	A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
title_full	A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
title_fullStr	A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
title_full_unstemmed	A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
title_sort	clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/755435f48dc141a399063455e8148dbe
work_keys_str_mv	AT yongzhuhe aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT kunhe aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT ruiqinhuang aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT liwenliu aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT shaoweiye aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT junlinqian aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT pengpeng aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT qijieluo aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT zeliangwang aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT zeminhu aclinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT yongzhuhe clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT kunhe clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT ruiqinhuang clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT liwenliu clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT shaoweiye clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT junlinqian clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT pengpeng clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT qijieluo clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT zeliangwang clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma AT zeminhu clinicalscoringsystemforpredictingtumorrecurrenceafterpercutaneousradiofrequencyablationfor3cmorlesshepatocellularcarcinoma
_version_	1718391318376349696

A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma

Ejemplares similares